vs
SAUL CENTERS, INC.（BFS）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
SAUL CENTERS, INC.的季度营收约是Day One Biopharmaceuticals, Inc.的1.9倍（$75.1M vs $39.8M），SAUL CENTERS, INC.净利率更高（8.7% vs -49.6%，领先58.2%），SAUL CENTERS, INC.同比增速更快（10.6% vs -57.6%）
Saul Centers, Inc.是一家总部位于美国的自主运营房地产投资信托，主要持有、运营及开发优质购物中心、混合用途物业与多户住宅资产，核心资产组合集中在华盛顿大都会区及美国其他精选高增长区域市场。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
BFS vs DAWN — 直观对比
营收规模更大
BFS
是对方的1.9倍
$39.8M
营收增速更快
BFS
高出68.2%
-57.6%
净利率更高
BFS
高出58.2%
-49.6%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $39.8M |
| 净利润 | $6.5M | $-19.7M |
| 毛利率 | — | — |
| 营业利润率 | 65.4% | -60.9% |
| 净利率 | 8.7% | -49.6% |
| 营收同比 | 10.6% | -57.6% |
| 净利润同比 | -19.6% | -153.3% |
| 每股收益（稀释后） | $0.15 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFSDAWN
| Q4 25 | $75.1M | — | ||
| Q3 25 | $72.0M | $39.8M | ||
| Q2 25 | $70.8M | $33.9M | ||
| Q1 25 | $71.9M | $30.8M | ||
| Q4 24 | $67.9M | — | ||
| Q3 24 | $67.3M | $93.8M | ||
| Q2 24 | $66.9M | — | ||
| Q1 24 | $66.7M | $0 |
净利润BFSDAWN
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $-19.7M | ||
| Q2 25 | $10.7M | $-30.3M | ||
| Q1 25 | $9.8M | $-36.0M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | $37.0M | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $13.6M | $-62.4M |
毛利率BFSDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.8% | — |
营业利润率BFSDAWN
| Q4 25 | 65.4% | — | ||
| Q3 25 | 69.1% | -60.9% | ||
| Q2 25 | 68.7% | -103.1% | ||
| Q1 25 | 66.5% | -133.5% | ||
| Q4 24 | 82.9% | — | ||
| Q3 24 | 72.8% | 31.6% | ||
| Q2 24 | 75.0% | — | ||
| Q1 24 | 72.4% | — |
净利率BFSDAWN
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | -49.6% | ||
| Q2 25 | 15.1% | -89.4% | ||
| Q1 25 | 13.6% | -117.0% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | 39.5% | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 20.4% | — |
每股收益（稀释后）BFSDAWN
| Q4 25 | $0.15 | — | ||
| Q3 25 | $0.32 | $-0.19 | ||
| Q2 25 | $0.33 | $-0.29 | ||
| Q1 25 | $0.29 | $-0.35 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.48 | $0.38 | ||
| Q2 24 | $0.48 | — | ||
| Q1 24 | $0.45 | $-0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.7M | $451.6M |
| 总债务越低越好 | $468.4M | — |
| 股东权益账面价值 | $307.8M | $450.9M |
| 总资产 | $2.2B | $513.8M |
| 负债/权益比越低杠杆越低 | 1.52× | — |
8季度趋势，按日历期对齐
现金及短期投资BFSDAWN
| Q4 25 | $8.7M | — | ||
| Q3 25 | $11.8M | $451.6M | ||
| Q2 25 | $5.3M | $453.1M | ||
| Q1 25 | $6.5M | $473.0M | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $7.2M | $558.4M | ||
| Q2 24 | $6.9M | — | ||
| Q1 24 | $7.1M | $317.9M |
总债务BFSDAWN
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益BFSDAWN
| Q4 25 | $307.8M | — | ||
| Q3 25 | $316.6M | $450.9M | ||
| Q2 25 | $322.4M | $460.8M | ||
| Q1 25 | $328.4M | $479.5M | ||
| Q4 24 | $335.8M | — | ||
| Q3 24 | $341.8M | $555.5M | ||
| Q2 24 | $345.7M | — | ||
| Q1 24 | $347.1M | $296.8M |
总资产BFSDAWN
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $513.8M | ||
| Q2 25 | $2.1B | $519.0M | ||
| Q1 25 | $2.1B | $534.4M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | $600.8M | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | $326.6M |
负债/权益比BFSDAWN
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.8M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 15.35× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BFSDAWN
| Q4 25 | $99.8M | — | ||
| Q3 25 | $20.6M | $-5.8M | ||
| Q2 25 | $26.6M | $-24.8M | ||
| Q1 25 | $30.4M | $-59.0M | ||
| Q4 24 | $121.2M | — | ||
| Q3 24 | $26.5M | $50.8M | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $33.8M | $-49.7M |
自由现金流BFSDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.3M | $50.0M | ||
| Q2 24 | $-12.5M | — | ||
| Q1 24 | $-11.7M | — |
自由现金流率BFSDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -192.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.1% | 53.4% | ||
| Q2 24 | -18.7% | — | ||
| Q1 24 | -17.6% | — |
资本支出强度BFSDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 81.5% | 0.8% | ||
| Q2 24 | 66.7% | — | ||
| Q1 24 | 68.3% | — |
现金转化率BFSDAWN
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | 1.37× | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFS
暂无分部数据
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
